
CHS Inc.
CHSCLNASDAQConsumer Defensive● Active
$25.59
$-0.21(-0.81%)
Market Cap$314040480
P/E Ratio—
52W High$26.089
52W Low$25.15
CHS Inc.(CHSCL)· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · CHSCL · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-08 | 2024-08 | 2023-08 | 2022-08 | 2021-08 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $35.46B | $39.26B | $45.59B | $47.79B | $38.45B |
| Cost of Revenue | $34.33B | $37.51B | $42.81B | $45.10B | $36.57B |
| Gross Profit | $1.14B | $1.75B | $2.78B | $2.69B | $1.88B |
| Gross Margin %(computed) | 3.21% | 4.46% | 6.10% | 5.63% | 4.88% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.75B |
| Total Operating Expenses | $1.05B | $1.17B | $1.03B | $1.00B | $0.75B |
| Operating Income | $0.09B | $0.58B | $1.75B | $1.69B | $1.13B |
| Operating Margin %(computed) | 0.26% | 1.49% | 3.84% | 3.54% | 2.94% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.11B | $0.10B |
| Interest Expense | $0.15B | $0.10B | $0.14B | $0.12B | $0.11B |
| Income Before Tax | $0.61B | $1.10B | $2.01B | $1.81B | $0.52B |
| Income Tax Expense | $0.02B | ($0.00B) | $0.11B | $0.13B | ($0.04B) |
| Net Income | $0.60B | $1.10B | $1.90B | $1.68B | $0.55B |
| Net Margin %(computed) | 1.69% | 2.81% | 4.17% | 3.51% | 1.44% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | $1.41B | $1.68B | $2.61B | $2.39B | $1.08B |
| EBITDA Margin %(computed) | 3.98% | 4.29% | 5.72% | 4.99% | 2.81% |
数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · USD · B
深入了解CHS Inc.
关于CHS Inc.(CHSCL)损益表
CHS Inc.(CHSCL)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,CHSCL实现营收$35.46B,毛利润$1.14B(毛利率3.21%),净利润$0.60B(净利率1.69%)。
常见问题
CHSCL · 4 问CHS Inc.(CHSCL)2025财年营收为$35.46B,同比down9.7%。
CHSCL revenueCHSCL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08